You are here: Industry Insights > Jazz

News List

Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults drugs
August 16, 2021
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of idiopathic hypersomnia in adults.
UK approval for Epidyolex to treat seizures from tuberous sclerosis pharmatimes
August 11, 2021
Jazz Pharmaceuticals subsidiary GW Pharmaceuticals has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for its cannabidiol Epidyolex as an adjunctive treatment of seizures associated with tuberous sclerosis ...
Stand Up To Cancer And Jazz Pharmaceuticals Collaborate To Fund Catalyst Research On Hard-To-Treat Cancers americanpharmaceuticalreview
August 11, 2021
Stand Up To Cancer® and Jazz Pharmaceuticals plc announce a three-year, $4 million research collaboration to explore new opportunities, including lurbinectedin in pediatric solid tumors and pan-RAF molecules in RAF- and RAS-mutated solid cancers.
Ligand Partner Jazz Pharmaceuticals Launches RYLAZE (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458 firstwordpharma
July 22, 2021
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has launched Rylaze™(asparaginase erwinia chrysanthemi (recombinant)-rywn), also known as JZP458.
Jazz Pharma’s blood cancer therapy Rylaze wins US approval pharmatimes
July 02, 2021
The US Food and Drug Administration has approved Dublin-based Jazz Pharmaceutical’s Rylaze for the treatment of two blood cancers – acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL).
Healthcare industry reported 85 deals worth $30 billion in Feb 2021 expresspharma
March 08, 2021
In February 2021, the healthcare industry reported 85 deals worth $30 billion as compared to last 12-month average (February 2020 to January 2021) of 88 deals worth $17.3 billion.
Jazz Pharma to buy GW Pharma for $7.2 billion, adding cannabis-based drug to portfolio expresspharma
February 04, 2021
The deal will allow Jazz to move beyond sleep disorders and cancer treatments by beefing up its neuroscience unit.
Jazz Pharma Acquires Redx Pharma's pan-RAF Inhibitor Program contractpharma
July 11, 2019
Has the potential to work in RAF driven tumors where current selective B-RAF inhibitors are ineffective due to acquired resistance mechanisms.
Jazz and Codiak collaborate on creating engineered exosomes for cancer pharmaceutical-technology
January 07, 2019
Jazz Pharmaceuticals has announced a collaboration with Codiak Biosciences to research, develop and commercialise cancer therapies created through engineering exosomes......
Jazz hiring 100-plus sales representatives to prep for new narcolepsy and AML launches fiercepharma
August 21, 2018
Jazz Pharmaceuticals is closing in on two new approvals, one on each side of the Atlantic, and it's staffing up to hit the ground running on both launches.